Measuring the action of CPP-siRNA conjugates in the lung
Sterghios A Moschos1, Karen G Spink, Mark A Lindsay
1Biotherapeutics, Pfizer Global Research and Development, Pfizer Inc, Sandwich, Kent, UK.
Methods in Molecular Biology (Clifton, N.J.)
|November 6, 2010
Summary
This study details methods for delivering short interfering RNA (siRNA) using cell-penetrating peptides (CPPs) to lung cells. It provides protocols for analyzing siRNA delivery and impact within the lung tissue.
Area of Science:
- Biologics development
- RNA interference (RNAi) therapeutics
- Cell-penetrating peptide (CPP) delivery systems
Background:
- Cell-penetrating peptides (CPPs) and RNA interference (RNAi) modulators are key areas in biologics development.
- Combining CPPs and RNAi presents challenges in achieving effective delivery of RNAi cargoes.
- The lung offers a model system for studying local delivery and impact of CPP-conjugated RNAi modulators.
Purpose of the Study:
- To present updated protocols for studying endogenous RNAi function.
- To detail the utility of CPPs for delivering short interfering RNA (siRNA) to lung cells.
- To provide methods for analyzing the local impact of CPP-conjugated RNAi modulators in the lung.
Main Methods:
- Sample collection, preservation, and processing for qualitative and quantitative delivery analysis.
- In situ hybridization for mapping siRNA delivery within lung tissue.
- Protocols for studying endogenous RNAi and CPP-mediated siRNA delivery.
Main Results:
- Established methodologies for assessing siRNA delivery to therapeutically relevant lung cells.
- Provided a framework for analyzing the local effects of CPP-siRNA conjugates.
- Detailed protocols facilitate the study of CPP-mediated RNAi in lung tissue.
Conclusions:
- CPP-conjugated RNAi modulators offer a promising strategy for lung-targeted therapies.
- The presented protocols enable robust analysis of siRNA delivery and efficacy in the lung.
- This work supports the advancement of RNAi-based therapeutics for respiratory diseases.
